Patient-specific tumor neoantigen peptide-Major Histocompatibility Complex (NeoAg-MHC)

Patient-specific tumor neoantigen peptide-Major Histocompatibility Complex (NeoAg-MHC) complexes are unique molecular targets formed when somatic mutations in a patient's tumor genome result in novel protein sequences (neoantigens) that are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules (Schumacher & Schreiber, 2015). Unlike tumor-associated antigens, which are also found in normal tissues, neoantigens are entirely tumor-specific, making them ideal targets for precision immunotherapy with minimal off-target effects on healthy cells (Ott et al., 2017). These complexes are recognized by the T-cell receptors (TCRs) of CD8+ and CD4+ T cells, triggering a targeted immune response against the malignancy (Sahin et al., 2017). Therapeutic strategies targeting these complexes include personalized mRNA or peptide vaccines designed to prime the immune system, as well as adoptive cell therapies like TCR-engineered T cells (TCR-T) (Blass & Ott, 2021). The efficacy of these treatments often depends on the quality of the neoantigen, its binding affinity to the patient's specific HLA alleles, and the presence of a robust T-cell repertoire. However, challenges remain, such as the heterogeneity of neoantigen expression within a tumor and the potential for tumors to escape immune detection by downregulating MHC expression or through other mechanisms of immune checkpoint activation.

Other names

Tumor-specific antigens (TSAs)NeoepitopesNeoantigen-HLA complexesMutation-derived antigensTumor neoantigens

Induction of a specific T-cell mediated immune response where T-cell receptors (TCRs) recognize the neoantigen peptide presented by MHC molecules, leading to the targeted destruction of tumor cells.